Drug pricing reform should be predictable

The main reason why companies want the pharmaceutical market and the pricing and reimbursement system to be predictable and transparent is that pharmaceutical R&D investment is very long-term and carries a significant risk of failure, the Korea Pharmaceutical Manufacturers Association said in a statement.

In an address commemorating its 66-year founding, the KPMA president Lee Kyung said tha...